Status:
COMPLETED
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combina...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Healthy male and female subjects
- Exclusion criteria:
- \- Any relevant deviation from healthy condition.
Exclusion
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02230995
Start Date
September 1 2014
End Date
October 1 2014
Last Update
March 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Biberach an der Riss, Germany